INTRODUCTIONAsthma is a complex heterogeneous respiratory disease characterized by variable airflow limitation and/or airway hyperresponsiveness. The disease is among the most common chronic illnesses in the human experience, affecting about 300 million people worldwide. The incidence of new‐onset adult asthma appears on the rise in industrialized countries, with estimates ranging from <1 to 11 cases per 1000 person‐year among published reports, but settling on about 2 per 1000 person‐years among persons aged 20‐50 years in large prospective studies. The broad category of work‐related asthma comprises adult onset asthma cases that are either caused by workplace exposures (ie, occupational asthma) or are a preexisting disease that is worsened by work factors (work‐exacerbated asthma). Estimates of the fraction of adult asthma that is work‐related have widely varied, but typically range between 10 and 25% in industrialized countries.De novo occupational asthma (OA) is induced via sensitization to a specific substance in the workplace, or by exposure to an inhaled irritant at work. There are over 300 causal agents for OA, which are broadly separated into proteinaceous substances (eg, natural rubber latex, enzymes, and animal‐derived antigens), and low‐molecular weight (LMW) chemicals (eg, isocyanates and acid anhydrides). Among known LMW agents, isocyanates, such as
American Journal of Industrial Medicine – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera